Five Travere Therapeutics Executives Sold Over $51 Million in Stock Together
CEO Eric Dube's $25.4 million sale led a wave of disposals by the company's top leadership, all disclosed within the same reporting window.
Travere Therapeutics' CEO, EVP, CFO, R&D chief and legal chief together sold more than $51 million in company stock, a concentration of insider selling across nearly the entire executive suite.
SPECIAL REPORTBEARISH